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Abstract
Radiation therapy (RT) continues to be one of the most popular treatment options for localized prostate cancer
(CaP). The purpose of the study was to investigate the in vitro effect of LBH589 alone and in combination with RT on
the growth and survival of CaP cell lines and the possible mechanisms of radiosensitization of this combination
therapy. The effect of LBH589 alone or in combination with RT on two CaP cell lines (PC-3 and LNCaP) and a
normal prostatic epithelial cell line (RWPE-1) was studied by MTT and clonogenic assays, cell cycle analysis,
western blotting of apoptosis-related and cell check point proteins, and DNA double strand break (DSB) repair
markers. The immunofluorescence staining was used to further confirm DSB expression in treated CaP cells. Our
results indicate that LBH589 inhibited proliferation in both CaP and normal prostatic epithelial cells in a time-and-
dose-dependent manner; low-dose of LBH589 (IC20) combined with RT greatly improved efficiency of cell killing in
CaP cells; compared to RT alone, the combination treatment with LBH589 and RT induced more apoptosis and led to
a steady increase of sub-G1 population and abolishment of RT-induced G2/M arrest, increased and persistent DSB,
less activation of non-homologous end joining (NHEJ)/homologous recombination (HR) repair pathways and a panel
of cell cycle related proteins. These results suggest that LBH589 is a potential agent to increase radiosensitivity of
human CaP cells. LBH589 used either alone, or in combination with RT is an attractive strategy for treating human
CaP.
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Introduction
Current treatment options for localized CaP are radiation
therapy (RT), surgery and endocrine therapy. Although
aggressive radiation does improve biochemical control, greater
rectal and urinary toxicities also occurred [1]. Local failure after
RT remains 20%–35% in intermediate- and high-risk CaP
patients [2], leading to increased metastasis and lower survival.
Thus, investigation of a novel combination approach with a
selective radio-sensitizer with RT to enhance CaP
radiosensitivity is urgently needed.
Histone deacetylase inhibitors (HDACi) are an emerging
group of agents which targets histone deacetylase (HDAC) and
promising radiosensitizers currently under investigation.
Radiosensitization by HDACi, such as valproic acid [3] has
been demonstrated in preclinical studies. HDACi is a potent
inducer or regulator of cellular behaviours such as apoptosis,
cell cycle and DNA repair processes. It is believed to exert its
effects mainly by modifying histone and chromatin structures,
thus modulate gene transcription [4]. Moreover, these
acetylases and deacetylases can also modulate cell functions
independent of gene expression by acting on non-histone
proteins such as p21 [5], p53 [6], Ku70 [6]. Through acting on a
series of histone and non-histone proteins, HDACi is capable of
mediating apoptosis, cell cycle, and DNA repair processes in a
well orchestrated manner.
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LBH589 is a hydroxamic acid derivative and a novel pan-
HDACi [7]. Qian et al. reported that LBH589 alone reduced
angiogenesis and tumor growth in a PC-3 xenograft animal
model [8]. A phase I study has been conducted by treating
castration-resistant prostate cancer (CRPC) patients using oral
LBH589 with or without docetaxel, demonstrating promising
results for future clinical application [9]. These results support
the hypothesis that LBH589 may be useful in combination with
RT for treating localized CaP.
In this study, we hypothesized that LBH589 could kill CaP
cells and treatment of CaP cells with LBH589 before RT would
increase the sensitivity of CaP cells to RT.
Materials and Methods
Chemicals and antibodies
LBH589 (panobinostat) was purchased from Selleck
Chemicals (Selleck Chemicals South Loop West, Houston, TX,
USA). Other chemicals used were purchased from Sigma-
Aldrich (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, Australia),
unless specified otherwise. Primary and secondary antibodies
used in this study are listed in Table 1.
Cell culture
The androgen-non-responsive PC-3 and androgen-
responsive LNCaP CaP cell lines, and the normal human
prostate RWPE-1 cell line were obtained from American Type
Culture Collection (ATCC) (Rockville, MD, USA). PC-3 and
LNCaP cells were cultured in RPMI-1640 supplemented with
10% (vol/vol) heated-inactivated fetal bovine serum (FBS), 50
U/mL of penicillin, and 50 µg/mL of streptomycin while RWPE-1
cells were cultured in K-SFM medium supplemented by 0.2
ng/mL recombinant epidermal growth factor (rEGF) and 25
µg/mL bovine pituitary extract without FBS. All cell lines were
maintained in a humidified incubator at 37°C and 5% CO2.
MTT assay
Cell proliferation was evaluated in CaP and normal prostate
cell lines after LBH589 treatment using MTT assay following a
published method [10]. Briefly, 2000 cells were seeded in 96-
well plates incubated in culture media for 24 h. Cells were then
treated with a range of concentrations of LBH589 (0 ~ 20
µmol/L) or the same volume of DMSO control in fresh media for
another 24, 48 and 72 h, respectively. The absorbance (OD)
was read at 560 nm on a BIO-TEC micro-plate reader (BIO-
RAD, Hercules, CA, USA). Each experiment was repeated at
least three times. Results are represented as the OD ratio of
Table 1. Antibodies used for western blotting and immunofluorescence staining.
Antibody Source Type Dilution Incubation time Temperature Application
Rabbit anti-human Caspase-3 (Pro) Epitomics MAb 1:1000 o/n 4°C WB
Rabbit anti-human Caspase-3 (Active) Epitomics MAb 1:1000 o/n 4°C WB
Rabbit anti-human Histone H3 (acetyl K9) Abcam PAb 1:500 o/n 4°C WB
Rabbit anti-human Histone H4 (acetyl K8) Abcam PAb 1:500 o/n 4°C WB
Rabbit anti-human p21 Abcam PAb 1:1000 o/n 4°C WB
Rabbit anti-human p-p53 Abcam PAb 1:1000 o/n 4°C WB
Mouse anti-human p53 Abcam MAb 1:1000 o/n 4°C WB
Rabbit anti-human phospho-CDK1 (Tyr15) Cell Signaling Technology PAb 1:1000 o/n 4°C WB
Rabbit anti-human Cdk1 (cdc2) Abcam PAb 1:10000 o/n 4°C WB
Rabbit anti-human p-Chk-1 Abcam PAb 1:1000 o/n 4°C WB
Rabbit anti-human Chk-1 Abcam PAb 1:1000 o/n 4°C WB
Rabbit anti-human p-Chk-2 Abcam PAb 1:500 o/n 4°C WB
Rabbit anti-human Chk-2 Abcam PAb 1:500 o/n 4°C WB
Rabbit anti-human phospho-Rb (Ser795) Cell Signaling Technology PAb 1:1000 o/n 4°C WB
Rabbit anti-human phospho-Rb (Ser807/811) Cell Signaling Technology PAb 1:1000 o/n 4°C WB
Mouse anti-human Rb Abcam MAb 1:1000 o/n 4°C WB
Mouse anti-human γH2AX Abcam MAb  1:500 (IF) 1:1000 (WB) o/n 4°C IF WB
Rabbit anti-human Ku70 Epitomics PAb 1:1000 o/n 4°C WB
Rabbit anti-human Ku80 Epitomics PAb 1:1000 o/n 4°C WB
Mouse anti-human BRCA1 Abcam MAb 1:200 (IF) 1:200 (WB) o/n 4°C WB, IF
Rabbit anti-human BRCA2 Abcam PAb 1:200 (IF) 1:1000 (WB) o/n 4°C WB, IF
Mouse anti-human RAD51 Abcam PAb 1: 100 (IF) 1:1000 (WB) o/n 4°C WB, IF
Mouse anti-human GAPDH Millipore MAb 1:500 o/n 4°C WB
Mouse anti-human IgG1-negative control Dako IgG1 1:1000 o/n 4°C IF
Goat anti-rabbit IgG-HRP Santa Cruz Biotechnology IgG 1:5000 45 min room temperature WB
Goat anti-mouse IgG-HRP Santa Cruz Biotechnology IgG 1:5000 45 min room temperature WB
Goat anti-mouse Alexa Fluor® 488 Dye Conjugate Invitrogen IgG 1:1000 45 min room temperature IF
Notes: MAb: monoclonal antibody; o/n: overnight; PAb: polyclonal antibody; WB: western blotting; IF: immunofluorescence; HRP: horseradish peroxidas
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the treated and control cells. IC20 (20% inhibitory concentration)
of LBH589 at 24 h was calculated and chosen for the following
experiments.
Colony forming assay
PC-3, LNCaP and RWPE-1 cells were used for colony
forming assays as described previously with minor
modifications [10]. Briefly, 1.5~2×106 PC-3, LNCaP and
RWPE-1 cells were treated in 6 cm dish with LBH589 at the
respective IC20 concentrations or same volume of DMSO
(control) for 24 h and then 200~2×105 cells were seeded in 6
cm dishes. After 8 h recovery, the LBH589-treated and DMSO-
treated control cells were exposed to a single dose irradiation
(0-8 Gy) at room temperature using a linear accelerator
(Elekta, Stockholm, Sweden) at a dose rate of 2.7 Gy/min with
6 MV photons (Cancer Care Centre, St George Hospital,
Sydney, Australia). After RT, all cells were immediately washed
with drug-free medium. After 14 days incubation, cells were
stained with crystal violet. The colonies, defined as groups of
>50 cells, were scored manually with the aid of an Olympus
INT-2 inverted microscope (Tokyo, Japan). Data from RT alone
or combination treated (LBH589 and RT) cells were normalized
against the un-irradiated cells (scored as 100% colony forming
ability).
Flow cytometric analysis for cell cycle distribution
0.5~2×106 PC-3 and LNCaP CaP cells were plated in 10 cm
dish for 24 h, then treated with LBH589 at the respective IC20
concentrations or DMSO (control) for another 24 h before
subjected to 2 Gy RT. At specific time points (pre-RT, 2, 6, 12,
24, 48 and 72 h after 2 Gy), trypsinized adherent and floating
cells were pooled and fixed in cold 70% (v/v) ethanol at 4°C.
Histograms of DNA content were analysed using FlowJo
software (V.7.6.1, Tree Star, Inc., Oregon, USA) to determine
cell cycle distribution (subs G1, G1, S, and G2/M).
Immunofluorescent staining for γH2AX and HR repair
pathway proteins
PC-3 and LNCaP CaP cells were treated with the same
protocol as described in cell cycle analysis (see above). After
receiving 2 Gy RT, LBH589-treated and DSMO-treated cells
were subjected to immunofluorescence staining at specific time
points (pre-RT, 24, and 72 h after 2 Gy). The cell preparation
for immunofluorescence staining was as previously described
with modifications [11,12]. The stained cells were examined
using an FV300/FV500 Olympus laser scanning confocal
microscope (Olympus, Tokyo, Japan) and images were
captured. For each treatment condition, γH2AX, BRCA1,
BRCA2 and RAD51 foci were determined in at least 50 cells.
The counting of γH2AX, BRCA1, BRCA2, and RAD51 nuclear
foci in these cells was performed by two independent
observers (WWX and JLH).
Western blotting
PC-3 and LNCaP CaP cells were treated with the same
protocol as described in cell cycle analysis (see above).
LBH589-treated and control cells were subjected to 2 Gy RT.
Both floating and adherent cells were collected at specific time
points (pre-RT, 2, 6, 12, 24, 48 and 72 h after 2 Gy) for western
blotting as described previously [13]. Membranes were
incubated with different primary antibodies and horseradish
peroxidise (HRP)-labelled secondary antibodies at specific
conditions (Table 1). ImageQuant LAS4000 system (GE Health
care, USA) was used for image recording.
Statistical analysis
All experiments were performed at least three times (n=3).
Results are presented as mean± standard deviation (SD). For
irradiation experiments, survival fractions were calculated as
followed: SF = [mean plating efficiency of radiation (±LBH589)
treated cells divided by mean plating efficiency of control
(±LBH589)] % Survival fractions of combination-treated cells
were corrected for the cytotoxicity of LBH589. RT survival
curves were fitted according to the linear-quadratic model using
GraphPad Prism 4.0 software (GraphPad, San Diego CA):
Survival = e-(αD+βD2)
The following parameters were calculated: α value, β value,
α/β value, ID90, ID50, and ID10 (RT dose producing a surviving
fraction of 10%, 50%, and 90%, respectively); and SF2
(surviving fraction at 2 Gy). The radiosensitizing effect of
LBH589 was represented by the dose enhancement factor
(DEF), calculated as the ID50 for RT treated cells divided by the
ID50 for combination-treated cells [14]. Two-way ANOVA was
used to study the influence of RT dose and LBH589 on the
outcome parameters (e.g., survival fraction, cell cycle
distribution, γH2AX foci number). A two-sample t test was used
to compare the mean percentage of subs G1, G1, S, and G2/M
phase cells and the mean γH2AX, BRCA1, BRCA2, RAD51
foci number between specific two treatment conditions.
Possible significant differences (p<0.05) were evaluated using
SPSS v 16.0 software (SPSS, Chicago, IL, USA).
Results
The effect of LBH589 alone on cell proliferation using
CaP cells and normal prostate epithelial cells
The time and dose-dependent cell proliferation inhibition
effect was found in both CaP cells (PC-3 and LNCaP) and
normal prostate epithelial cells (RWPE-1) (Figure 1A). IC20
value at 24 h for PC-3, LNCaP and RWPE-1 was 10 µmol/L,
2.5 µmol/L, and 15 µmol/L, respectively, suggesting that two
CaP cell lines are more sensitive to LBH589 than the normal
prostate epithelial cell line.
The effect of combination treatment on colony
formation using CaP and normal prostate cells
The radiosensitization effect of LBH589 on PC-3 and LNCaP
was indicated by significantly reduced survival fractions
(p=0.0075 for PC-3, p=0.0074 for LNCaP) and DEF in these
two cell lines >1 (1.77 for PC-3 and 1.29 for LNCaP) (Figure
1B-C). Radiosensitivity was not significantly increased in
RWPE-1 by LBH589 pretreatment with DEF of 1.18 (p=0.0823)
(Figure 1B-C). RT parameters for RT alone and combination
treatment in each cell line are summarized in Table 2. SF2,
Combination Therapy for Prostate Cancer
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ID90, ID50 and ID10 were all significantly decreased in PC-3
and LNCaP by LBH589 pretreatment (p<0.05), but none of
these significantly changed for RWPE-1.
LBH589 alone can induce apoptosis and histone
acetylation in CaP cells
Low-dose of LBH589 treatment (IC20) for 24 h induced
cleavage of full length caspase-3 and acetylation of histone 3
(H3) and histone 4 (H4) in both PC-3 and LNCaP cells (Figure
Figure 1.  Effect of LBH589 on cell growth and effect of RT or combination treatment (LBH589 and RT) on colony forming
in CaP cell lines and normal epithelial prostate cell line.  (A) Cells were treated with a range of concentrations of LBH589 for 24,
48 and 72 h; (B) Cells were treated with RT or combination with RT and LBH589 for analysis of colony-forming efficiency. Survival
fractions were significantly reduced in PC-3 and LNCaP CaP cells (p<0.01), but not in normal REWP-1 cells (p>0.05); (C) Typical
images are shown for colony growth in RT and combination treatment (LBH589 and RT) in CaP and normal prostate cells. All
results were from three independent experiments (N=3). Points, mean; bars, SD.
doi: 10.1371/journal.pone.0074253.g001
Combination Therapy for Prostate Cancer
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e74253
S1), suggesting LBH589 may initiate apoptosis pathway related
to histone acetylation.
Effect of combination treatment or RT alone on cell
cycle distribution
Percentage of subG1 population increased steadily and
significantly in the combination-treated cells compared to RT-
treated cells in both CaP cell lines (Figure 2 and Figures S2-
S5), indicating more cell death including apoptosis in
combination-treated cells. Upon RT treatment alone, the cells
underwent temporary cell cycle delay/G2/M arrest between 2–
24 h, and then eventually recovered after 24 h. Accordingly, RT
reduced G1 population between 2–24 h, and the G1 resumed
after 24 h (Figure 2). Whereas, in combination treatment
(LBH589+RT), the LBH589 pre-treatment on cells initially
triggered an augment of G2/M arrest accompanied with the
decrease of G1 and S portions. The combination treatment
then caused the subsequent and gradual abolishment of all G1,
S and G2/M populations of treated cells with a minimum
recovery (Figure 2).
Differences in the G2/M subpopulation between combination-
treated and RT-treated groups in each CaP cell line were also
observed. Cells that only received 2 Gy RT had significant
G2/M arrest 6~12 h after RT in both PC-3 and LNCaP cell
lines, and G2/M arrest persisted in the LNCaP cells until 48 h
post RT. For combination treated cells, initial LBH589
treatment caused a significant increase of G2/M population
percentage prior to RT in both CaP cell lines, and abolished
further G2/M arrest after subsequent 2 Gy RT (Figure 2 and
Figures S2-S5).
Combination treatment can inhibit RT-induced cell
cycle checkpoints activation in CaP cells
The patterns of expression for these checkpoint proteins
differed in two CaP cell lines after RT alone or combination
treatment with LBH589 and RT are shown in Figure 3. As p53
is negative in PC-3 cells, the expression of both p21 and p53
increased after 2 Gy RT or combination treatment in LNCaP
cells, but they are more persistent in RT treatment alone
compared to the combination treatment. The patterns of p21
expression in single or combination treatments in PC-3 cells
are very similar to those in LNCaP cells. p21 in either PC-3 or
LNCaP cells and p53 in LNCaP cells were not detectable 24 h
after combination treatment because LBH589 pretreatment led
to gradual decrease of p21 and p53 expression (Figure 3).
Expression of p-CDK1 was observed in RT-treated cells before
RT and was persistent until 72 h after 2 Gy RT in both PC-3
and LNCaP cells; in contrast, its expression was down-
regulated and even became undetectable in combination-
treated groups (Figure 3). The expression of total-Cdk1 (t-
Cdk1) did not change with time, and remained at similar level
after single RT and combination treatment (Figure 3).
The expression levels of total-Chk-1 (t-Chk-1) and total-
Chk-2 (t-Chk-2) (two important checkpoint kinases in cell cycle
control) upon DNA damage were increasing with post RT time
in RT alone group. The addition of LBH589 did not alter the
radiation-induced increase in t-Chk-1 and t-Chk-2, but
abrogated the increase at all time points (Figure 3).
Combination treatment of LBH589 and RT led to markedly
diminished level of activated Chk-1 and Chk-2 (p-Chk-1 and p-
Chk-2) after 6 h post RT treatment, as compared to RT
treatment alone (Figure 3). The expression of checkpoint
proteins is expected to protect cells from radiation. Our results
suggest that LBH589 may affect both the expression and the
activity of Chk-1 and Chk-2 thus interfering cell cycle
management when combined with RT treatment. p-Rb795 and
p-Rb807/811 proteins are important checkpoints responsible
for G2/M arrest of cancer cells to RT. Activation of these two
proteins was detected in RT-treated cells while no, or very
weak expression of these two proteins were detected in
combination-treated cells, whereas there was no obvious
change detected for the expression of total-Rb (t-Rb) (Figure
3), which means that LBH589 pretreatment inhibited RT-
induced activation of p-Rb795 and p-Rb807/811. Collectively,
these results indicate that expression and activation of these
cell-cycle related checkpoint proteins are altered in
combination-treated groups, compared to RT alone-treated
groups.
Combination treatment can induce persistent DNA
double strand break (DSB) in CaP cells
DNA DSB was examined using γH2AX as a marker by
western blotting and fluorescence staining. In 2 Gy RT-treated
CaP cells, the expression of γH2AX started to increase from
10–15 min after RT, peaking at 48 h and 2 h, for PC3 and
LNCaP respectively, as shown by western blotting (Figure 3).
The γH2AX results from western blotting were further
confirmed by immunofluorescence staining (Figure 4). In
Table 2. Radiobiological parameters for radiation and LBH589-radiation treatment.
Cell line Subgroup α value (Gy-1) β value (Gy-2) α/β value (Gy) SF2 ID90 ID50 ID10 DEF (ratio of ID50)
PC-3 Radiation 0.259 0.064 4.047* 0.46* 4.31* 1.84* 0.37* 1.77
 LBH589-radiation 0.542 0.119 4.555 0.21 2.68 1.04 0.19  
LNCaP Radiation 0.028 0.075 0.373* 0.70* 5.35* 2.86* 1.01* 1.29
 LBH589-radiation 0.053 0.118 0.424 0.56 4.20 2.21 0.75  
RWPE-1 Radiation 1.0E-07 0.038 2.6E-06 0.86 7.78 4.27 1.67 1.18
 LBH589-radiation 0.039 0.042 0.918 0.78 6.92 3.61 1.18  
Abbreviations: SF2 = surviving fraction at 2 Gy; ID90 = radiation dose producing a surviving fraction of 90%; ID50 = radiation dose producing a surviving fraction of 50%;
ID10 = radiation dose producing a surviving fraction of 90%; DEF = dose enhancement factor; *p<0.05 vs. corresponding LBH589-radiation treated cells.
Combination Therapy for Prostate Cancer
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e74253
Figure 2.  Effects of RT or combination treatment (LBH589 and RT) on cell cycle arrest in PC-3 and LNCaP CaP cell
lines.  The percentage of subs G1, G1, S, and G2/M populations were analysed using flow cytometry from pre-RT to 72 h post-RT;
p<0.01(*): significant difference in the percentage of cell cycle phase between the indicated time point and the “Pre-RT” time point in
RT groups; p<0.01(#): significant difference in the percentage of cell cycle phase between the RT group and the combination group
at the “Pre-RT” time point; p< 0.01(&): significant difference in the percentage of cell cycle phase between the indicated time point
and the “Pre-RT” time point in combination group. All results were from three independent experiments (N=3). Points, mean; bars,
SD.
doi: 10.1371/journal.pone.0074253.g002
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contrast, for the cells treated with combination therapy, γH2AX
was moderately expressed at the pre-RT time point and was
up-regulated on the time scale in both PC-3 and LNCaP cells
until 72 h (Figure 3). Number of γH2AX foci in nuclei was
quantified as shown in Figure 4. Positive γH2AX foci were still
detectable 72 h after 2 Gy RT in PC-3 and LNCaP cells by
combination treatment. These results indicate that DNA DSB
persists after combination treatment compared to RT alone.
Combination treatment can decrease activation of non-
homologous end joining (NHEJ) repair pathway in CaP
cells
Since persistent DNA DSB were seen in combination-treated
cells, two NHEJ pathway proteins (Ku70 and Ku80) which are
responsible for repair of RT-induced DSB were further
examined by western blotting in RT- and combination-treated
cells. Expression patterns of Ku70 and Ku80 were different for
PC-3 and LNCaP cells (Figure 3). In PC-3 cells, positive
expression of Ku70 and Ku80 was found 6 h after RT and
increased gradually until 72 h after RT whereas expression of
Ku70 and Ku80 was undetectable after 48 h in combination
treatment (Figure 3). In LNCaP cells, positive expression of
Ku70 and Ku80 was found at all time points for RT alone and
combination treatment with LBH589 and RT, but expression
levels of Ku70 and Ku80 were much higher after RT alone
compared to combination treatment at all time points (Figure
3). These results indicate NHEJ pathway was involved in RT in
CaP cells and that pre-treatment with LBH589 can decrease its
activation compared to RT alone.
Combination treatment can decrease activation of
homologous recombination (HR) repair pathway in CaP
cells
BRCA-1, BRCA-2 and Rad-51 are the DSB repair proteins in
the HR pathway. The expression of these proteins was
increasingly induced from 2 h until 72 h after single RT by
western blotting (Figure 3). Compared to the RT alone group,
the expression of BRCA-1 and BRCA-2 proteins in the
combination treatment groups followed the same trend but was
abrogated after 6 h post RT in both cell lines. Especially, the
expression of RAD51 protein was maintained in a lower level
until 72 h in PC-3 cells and was markedly reduced until 24 h in
Figure 3.  Effects of RT or combination treatment (LBH589 and RT) on cell cycle checkpoints, DNA damage and repair
proteins in PC-3 and LNCaP CaP cells from pre-RT to 72 h post-RT.  Cell cycle related proteins (p21, p-p53, p53, p-Cdk1, t-
Cdk1, p-Chk1, t-Chk1, p-Chk2, t-Chk2, p-Rb795, p-Rb807/811, t-Rb) and DNA damage and repair related proteins (γH2AX, Ku70,
Ku80, BRCA1, BRCA2, and RAD51) were determined by western blotting. t: Changes in total protein levels upon DNA damage; p:
activation of DNA or cell cycle checkpoint proteins (phosphorylated form). Typical images are shown from three independent
experiments (N=3).
doi: 10.1371/journal.pone.0074253.g003
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LNCaP cells in the combination groups (Figure 3). The
BRCA-1, BRCA-2 and Rad-51 results from western blotting
were further confirmed by immunofluorescence staining
(Figures 5-7). Number of the foci from three protein repair
markers in nuclei was quantified as shown in Figures 5-7. The
results from the western blot were consistent with the
immunofluorescent staining results. Our findings suggest that
in addition to affecting NHEJ repair pathway, LBH589 may also
Figure 4.  Quantitative analysis of DNA double strand break (DSB) marker γH2AX foci at pre-RT, 24 h and 72 h after 2 Gy
RT or combination treatment in PC-3 and LNCaP cells.  (A) After 2 Gy RT, average γH2AX foci number increased significantly at
24 h in both PC-3 and LNCaP cells and decreased to a lower level at 72 h while average γH2AX foci number in combination-treated
(LBH589+2 Gy RT) cells was significantly higher than that in RT-treated cells at any time points and continued to increase until 72 h.
(B) Representative images of γH2AX staining after 2 Gy RT or combination treatment (LBH589+2 Gy RT) in PC-3 and LNCaP cells.
p<0.05(†) indicates significant difference between RT-treated cells and combination-treated cells at the same time point. p<0.05(*)
indicates significant difference between cells at specific time points and cells receiving the same treatment at the “Pre-RT” time
point. Points, mean; bars, SD. N=50. Typical images are shown from three independent experiments (N=3). Magnification × 60 in all
images.
doi: 10.1371/journal.pone.0074253.g004
Combination Therapy for Prostate Cancer
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sensitize RT via interfering HR pathway thus weakening DSB
repair ability of the CaP cells.
Discussion
In this study, we demonstrated that LBH589 inhibited the
growth of PC-3, LNCaP CaP cells and RWPE-1 normal
prostate epithelial cells in a dose and time-dependent manner,
which is similar to previously reported toxicities of other
hydroxamates [15]. The normal prostatic epithelial cell line
RWPE-1 was the most resistant to LBH589 while LNCaP was
the most sensitive among the three cell lines, suggesting CaP
cells are relatively sensitive to LBH589.
It has been recognized that α/β value is substantially lower in
CaP than most other cancers. The α/β values of PC-3 and
LNCaP cells in the current study are in line with previous
Figure 5.  Quantitative analysis of DSB repair marker in the HR pathway for BRCA1 foci at pre-RT, 24 h and 72 h after 2 Gy
RT or combination treatment in PC-3 and LNCaP cells.  (A) After 2 Gy RT, average BRCA1 foci number increased significantly
at 24 h in both PC-3 and LNCaP cells and maintained increased at 72 h, while average BRCA1 foci number in combination-treated
(LBH589+2 Gy RT) cells was also increased at 24 and 72 h, but was significantly lower than that in RT-treated cells. (B)
Representative images of BRCA1 staining after 2 Gy RT or combination treatment (LBH589+2 Gy RT) in PC-3 and LNCaP cells.
p<0.05(†) indicates significant difference between RT-treated cells and combination-treated cells at the same time point. p<0.05(*)
indicates significant difference between cells at specific time points and cells receiving the same treatment at the “Pre-RT” time
point. Points, mean; bars, SD. N=50. Typical images are shown from three independent experiments (N=3). Magnification × 60 in all
images.
doi: 10.1371/journal.pone.0074253.g005
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reports, which is between 0.5 and 4 Gy [16]. When cells
received combination treatment (LBH589 and RT), the α/β
values of PC-3 and LNCaP cells was increased to 4.555 and
0.424 Gy, respectively. DEF was 1.77 for PC-3 and 1.29 for
LNCaP. The α/β value of RWPE-1 normal prostate cell line was
0.243 and 0.257 Gy after RT alone or combined treatment,
which is correspondingly lower than the two CaP cell lines.
DEF was 1.18 which is less than that in PC-3 and LNCaP cell
lines. These results warrant further in vivo study and clinical
trials.
In the current study, our results demonstrated that even low
dose of LBH589 (IC20) for 24 h treatment could trigger
apoptosis in CaP cells (Figure S1) and the percentage of the
subG1 population cells in combination treatment of LBH589
and RT gradually increased while it was consistently quite low
in the RT treated cells, meaning that combination treatment
can induce more cell death.
Figure 6.  Quantitative analysis of DSB repair marker in the HR pathway for BRCA2 foci at pre-RT, 24 h and 72 h after 2 Gy
RT or combination treatment in PC-3 and LNCaP cells.  (A) After 2 Gy RT, average BRCA2 foci number increased significantly
at 24 h in both PC-3 and LNCaP cells and maintained increased at 72 h, while average BRCA1 foci number in combination-treated
(LBH589+2 Gy RT) cells was also increased at 24 and 72 h, but was significantly lower than that in RT-treated cells. (B)
Representative images of BRCA2 staining after 2 Gy RT or combination treatment (LBH589+2 Gy RT) in PC-3 and LNCaP cells.
p<0.05(†) indicates significant difference between RT-treated cells and combination-treated cells at the same time point. p<0.05(*)
indicates significant difference between cells at specific time points and cells receiving the same treatment at the “Pre-RT” time
point. Points, mean; bars, SD. N=50. Typical images are shown from three independent experiments (N=3). Magnification × 60 in all
images.
doi: 10.1371/journal.pone.0074253.g006
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Cell cycle analysis further confirmed that more PC-3 and
LNCaP cells were blocked in G2/M phase after 24 h LBH589
treatment and the percentage of cells in G1 phase decreased
significantly. Moreover, treatment with LBH589 for 24 h
reduced the S-phase content of LNCaP cells to a lower level. In
all the cell cycle phases, G2/M phase cells are the most
sensitive to radiation and S phase cells are the most resistant
[17]. Our results suggest that cell cycle arrest at G2/M and
decrease of S phase percentage might be responsible for the
radiosensitization effect of LBH589. The p53-p21 axis plays a
very important role in the regulation of cell cycle in CaP RT
[18,19]. The check point proteins Chk1/2-mediated p53
phosphoralation can result in the activation of p21 transcription,
thereby inhibits Cdk activity and leads to cell cycle arrest at G1
phase [20]. It was reported that up-regulation of p21 and its
subsequent binding to the CDK1-cyclin complexes [21] inhibit
CDK1 phosphorylation and lead to a G2/M cell cycle arrest
effect [22]. Here, we found that in the later time points (24 h, 48
Figure 7.  Quantitative analysis of DSB repair marker in the HR pathway for RAD51 foci at pre-RT, 24 h and 72 h after 2 Gy
RT or combination treatment in PC-3 and LNCaP cells.  (A) After 2 Gy RT, average RAD51 foci number increased significantly
at 24 and 72 h in both PC-3 and LNCaP cells, while average BRCA1 foci number in combination-treated (LBH589+2 Gy RT) cells
was also increased at 24 and 72 h, but was significantly lower than that in RT-treated cells. (B) Representative images of RAD51
staining after 2 Gy RT or combination treatment (LBH589+2 Gy RT) in PC-3 and LNCaP cells. p<0.05(†) indicates significant
difference between RT-treated cells and combination-treated cells at the same time point. p<0.05(*) indicates significant difference
between cells at specific time points and cells receiving the same treatment at the “Pre-RT” time point. Points, mean; bars, SD.
N=50. Typical images are shown from three independent experiments (N=3). Magnification × 60 in all images.
doi: 10.1371/journal.pone.0074253.g007
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h, 72 h), both p53 (PC-3 cell line is p53 negative) and p21
proteins were lower in the combination treatment compared to
those treated with RT alone, which is in accordance with the
G1 defect in cell cycle following the combination treatment in
the later time points. The initial increase of p21, p53 and
reduction of p-CDK1 after LBH589 treatment especially in
LNCaP cells indicate a potential mechanism for G2/M arrest
caused by LBH589. The deficiency of p53 in PC-3 cells
suggests that p21 may be regulated by alternative
mechanisms.
After radiation, G2/M arrest is a protective reaction which
enables cells to repair DNA damage before entering mitosis.
G2/M arrest caused by 2 Gy RT wasn’t detected in the
combination group. Correspondingly two cell cycle checkpoints,
p-Rb795 and p-Rb807/811, were activated after 2 Gy RT, but
combination treatment significantly reduced all their activation
in both PC-3 and LNCaP cells, indicating LBH589 treatment at
IC20 concentrations were effective to perturb CaP cells’
regulation of cell cycle after RT. These results may also explain
part of the radiosensitization effect of LBH589.
In our study, expression of γH2AX was enhanced by
combination treatment with LBH589 and RT in both PC-3 and
LNCaP cells, including LBH589-induced endogenous foci
before radiation as well as promoting the radiation-induced foci.
NHEJ and HR pathways are the most important two signaling
pathways responsible for repairing DNA DSBs. We found for
the first time that key proteins including Ku70 and Ku80 are
activated in PC-3 and LNCaP cells after RT and that both Ku70
and Ku80 proteins were less activated in CaP cells by LBH589
pretreatment, which implies that the NHEJ repair pathway
plays an important role in the regulation of CaP radiosensitivity
after exposure to RT.
HR pathway repairs DSB using a homologous chromatid or
chromosome [23]. It was reported that only ~10% of DSB were
repaired by the HR pathway in mammalian cells [24]. In the
current study, we have shown that the BRCA1, BRCA2 and
Rad51 proteins which are the main partakers in the HR
pathway, were presented with the delayed increase in the
combination treatment group, when compared to RT alone
group. Therefore, these HR repair pathway proteins are
involved in the radiosensitization effect induced by LBH589.
Given that LBH589 is a pan-HDACi, it may interfere with
activation of all these proteins by increasing acetylation. This
could be the possible reason why the DNA DSBs repair was
significantly impaired in the combination-treated CaP cells. Our
results are consistent with the observation by other group that
most of genes involved in cell cycle control, DNA replication
and DNA damage repair were downregulated after treatment
with HDACi [25]. Our findings indicate that both NHEJ and HR
repair pathways are involved in DNA repair defective in the
combination treatment.
The loss of histone lysine acetylation has been observed to
be related with carcinogenesis. Over the past decade, HDAC,
which is responsible for removing the acety group from
histones, have evolved as one of the major cancer targets for
epigenic based therapies [26]. Combining epigenic therapy with
HDACi or traditional regimens such as chemotherapy or RT is
a new developing research area in reducing toxicity in
chemotherapy and radiotherapy [27–30]. Like other HDACis,
the LBH589 (HDACi)-mediated radiosensitization might result
from several mechanisms: 1) the expression of check point and
DSB repair proteins were inhibited by HDACi [25]; 2) HDACi
mediated deacetylation may cause disruption of protein–protein
interaction during cell cycle control and DSB repair [31]; 3) the
HDACi treatment resolves the compact structure of the
chromatin, which may lead to the susceptibility of the cells to
radiation damage [32] and the activation of specific gene
transcription [33,34]. All above reasons may cause the defects
in DNA damage repair and checkpoint proteins which would
allow the cells to proceed through the cell cycle with damaged
DNA, resulting in more apoptosis. This phenomenon has been
shown for cell death upon chemo- and radiotherapy treatment
in several cancers [35]. Our study indicates that LBH589, even
in a low dose, is a potent radiosensitizer in CaP cells in vitro,
and cell cycle check point and DSB repair proteins (p21, p53,
Cdk1, Chk1, Chk2, Rb, γH2AX, Ku70, Ku80, BRCA-1,
BRCA-2, and RAD51) are activated in response to RT alone so
that the cells may gain sufficient time for DNA repair. After CaP
cells received the combination therapy (LBH589+RT), the
activation of these proteins were inhibited, leading to DNA
repair defect and the increase of radiosensitivity of CaP cells.
In summary, our results demonstrated for the first time that
LBH589 at low concentration (IC20) sensitizes CaP cells to RT.
The putative mechanisms of the radiosensitization effect in
CaP cells include induction of apoptosis; redistribution to a
more radiosensitive cell cycle phase and abolishment of RT-
induced cell cycle arrest; induction of more DNA damage and
inhibition of repair of RT-induced DNA DSBs through
diminishing NHEJ and HR pathways. Combination of LBH589
and RT may provide a new treatment strategy to improve anti-
cancer efficacy while reducing the toxicity of extreme high dose
RT.
Supporting Information
Figure S1.  Effects of LBH589 on expression of apoptotic
proteins and acetylated histones in CaP cells. After LBH589
treatment at IC20 concentrations for 24 h, expression of
Caspase-3 (Pro), Caspase-3 (Active)], acetylated H3 and
acetylated H4 was determined by western blotting in PC-3 and
LNCaP cells. The typical images are shown from three
independent experiments (N=3).
(TIF)
Figure S2.  Representative images of cell cycle histograms
of PC-3 cells after 2 Gy RT from 0- to 72 h post-RT.
(TIF)
Figure S3.  Representative images of cell cycle histograms
of PC-3 cells after combination treatment of LBH589 and 2
Gy RT from 0 to 72 h post-RT.
(TIF)
Figure S4.  Representative images of cell cycle histograms
of LNCaP cells after 2 Gy RT from 0 to 72 h post-RT.
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(TIF)
Figure S5.  Representative images of cell cycle histograms
of LNCaP cells after combination treatment of LBH589 and
2 Gy RT from 0 to 72 h post-RT.
(TIF)
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